PaCIFiC-CUP Classifies Cancer of Unknown Primary

Recruiting now

Conditions studied: Unknown Primary Tumors, DNA Methylation

In brief

This study aims to initially utilize machine learning on pan-cancer DNA methylation data from public databases to construct a DNA methylation classification model (PaCIFiC-CUP, pan-cancer integrated fingerprinting classifier of CUP) for diagnosing various types of cancer, particularly the primary site of cancer of unknown primary. The goal is to achieve diagnosis of cancer pathology type by analyzing the DNA methylation patterns of cancer specimens, thereby guiding subsequent precision treatment for cancer.

Key facts

Study ID

NCT06140992

Run by

Sun Yat-sen University

People needed

120

Starts

2023-07-01

Expected to finish

2026-12-31

Last updated by the study team

2026-04-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient specimens were obtained from the Sun Yat-sen University Cancer Center and affiliated cooperating centers, with written consent from the patients authorizing the use of the specimens for research purposes.
• Following standard assessments (medical history, physical examination, complete blood count, biochemistry, computed tomography scans of the neck, chest, abdomen, and pelvis, targeted evaluations of all symptomatic areas, pathology, and immunohistochemistry), the diagnosis was determined as a primary site unknown tumor (including adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, sarcoma, etc).
• The diagnosis was confirmed at the participating institution and the patient had received systemic therapy.
• Complete clinical, pathological, and follow-up data for the patients can be obtained.
• ECOG performance status score: 0-2 points.

You may not qualify if…

• Pregnant or lactating female patients.
• Tumor tissue sample size is too small (tumor tissue accounts for <70% in the biopsy or slice tissue).
• Organ transplant or history of non-autologous (allogeneic) bone marrow or stem cell transplantation.
• History of previous tumors, with the current condition being a recurrent tumor.
• Hematological malignancies (excluding lymphoma).
• Other diseases that may severely impact patient survival, such as severe cardiovascular or cerebrovascular diseases, sepsis, severe trauma or burns, etc.

Where it is running

• Sun Yat-sen university cancer center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.